stella
beta
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever — Stella
Home
/
Vaccine
/
View on ClinicalTrials.gov
Recruiting
Back to Vaccine trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
Flourish Research San Antonio (Clinical Trials of Texas), San Antonio, Texas